Theralase Completes Clinical Protocol
Filing Services Canada XHTML - Fri Sep 11, 6:04AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Successfully Completes GLP Toxicology Analysis of Lead Drug
Filing Services Canada XHTML - Thu Sep 10, 6:05AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Research Demonstrates Lead Drug Also Effective for Muscle Invasive Bladder Cancer
Filing Services Canada XHTML - Wed Sep 09, 6:01AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Completes GMP Manufacture of Lead Drug
Filing Services Canada XHTML - Tue Sep 08, 6:00AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Demonstrates Stability of Lead Drug
Filing Services Canada XHTML - Fri Sep 04, 6:00AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Expands Photo Dynamic Compound Pipeline
Filing Services Canada XHTML - Thu Sep 03, 6:03AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Releases 2Q2015 Financials
Filing Services Canada XHTML - Fri Aug 28, 3:03PM CDT
TLT.VN: 0.305 (+0.005)
Theralase Provides Corporate Update
Filing Services Canada - Mon Aug 17, 6:04AM CDT
Theralase Provides Corporate Update Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (Theralase or the Company) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has provided a comprehensive corporate update on a recent radio program entitled The Korelin Economics Report. These highlights include: Status of regulatory approval for next generation therapeutic laser Status of sales and marketing team for product launch Revenue expectations post product launch Full interview available here: http://www.kereport.com/2015/08/14/roger-whit...theralase/ (http://www.kereport.com/2015/08/14/roger-white-update-tlc2000-newest-product-theralase/) Roger Dumoulin-White, President and CEO, Theralase stated, Theralase is completing the final steps for commercialization of our next generation therapeutic laser as we await Canadian regulatory approval. Post launch, the Company will be in a position to demonstrate the enhanced efficacy that this next generation technology will bring to the worldwide pain market. About Theralase Technologies Inc. Theralase Technologies Inc. (Theralase(R)) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralases Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them. Additional information is available at www.theralase.com (http://www.theralase.com/) and www.sedar.com (http://www.sedar.com/) . Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license. This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. For More Information: Michael Borovec Director of Investor Relations 1.866.THE.LASE (843-5273) ext. 222 416.699.LASE (5273) ext. 222 mborovec@theralase.com (mailto:mborovec@theralase.com) www.theralase.com (http://www.theralase.com) To view this press release as a PDF file, click onto the following link: http://fscwire.com/sites/default/files/news_r...172015.pdf Source: Theralase Technologies Inc. (TSX Venture:TLT, OTC Pink:TLTFF) http://theralase.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
TLT.VN: 0.305 (+0.005)
Theralase Achieves 98% Destruction of Bladder Cancer
Filing Services Canada XHTML - Wed Jul 22, 6:15AM CDT
TLT.VN: 0.305 (+0.005)
Theralase Appoints Experienced Sales and Marketing Team to Launch Next Generation Therapeutic Laser
ACCESSWIRE - Fri Jul 17, 8:52AM CDT
TORONTO, ON / ACCESSWIRE / July 17, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company"
TLT.VN: 0.305 (+0.005)